Bridging and Validation of the Specific Graves Ophthalmopathy Quality of Life Questionnaire With Health State Utility Values
Authors' conclusion
Patients with moderate-to-severe active TED health states demonstrate increasing TED severity associated with declining utility values and worsening GO-QOL scores. These results indicate that the GO-QOL scores can be used to bridge to the HSU scores for benefit quantification.
Study context
- Population
- Patients with thyroid eye disease (TED) in 2 randomized, masked, placebo-controlled teprotumumab trials
- Participants
- 171 patients2 RCTs
- Comparison
- Graves Ophthalmopathy Quality of Life (GO-QOL) scores vs 6 health state utility (HSU) values by proptosis/diplopia severity
- Outcome
- GO-QOL vs TED severity and HSU
- Follow-up
- Baseline and after 6-month treatment
Methodological detailssecondary analysis of 2 randomised, masked, placebo-controlled teprotumumab trials, regression analyses, correlation with health state utility values
- Secondary analysis of 2 randomised, masked, placebo-controlled teprotumumab trials
- Regression analyses
- Correlation with health state utility values
Performance
As reported in the abstract
baseline and after 6-month treatment
Utility change per 1-point improvement in GO-QOL score with teprotumumab vs placebo
0.013
Original publication
Bridging and Validation of the Specific Graves Ophthalmopathy Quality of Life Questionnaire With Health State Utility Values. Endocr Pract. Published 8 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →